Novoheart, a subsidiary wholly-owned by Medera (www.linkedin.com/company/medera-biopharmaceutical), is responsible for Disease Modelling & Drug Discovery using our proprietary award-winning mini-Heart Technology, which offers a range of bioengineered human heart constructs including the world’s first human heart-in-a-jar as healthy and diseased human hearts for testing toxicity and efficacy. This platform enables us to uniquely model human-specific diseases and discover therapeutic candidates all in the context of human cells and tissues, free from species-specific differences. Before privatisation by Medera, Novoheart was dually listed on the Toronto Stock Exchange and Frankfurt Stock Exchange.